Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients

被引：54

作者：

Catarino, Raquel ^{[1
]}

Coelho, Ana ^{[1
]}

Araujo, Antonio ^{[2
]}

Gomes, Monica ^{[1
]}

Nogueira, Augusto ^{[1
]}

Lopes, Carlos ^{[1
,3
]}

Medeiros, Rui ^{[1
,3
,4
,5
]}

机构：

[1] Portuguese Inst Oncol, Mol Oncol Grp Invest Ctr, Oporto, Portugal

[2] Portuguese Inst Oncol, Dept Med Oncol, Oporto, Portugal

[3] Abel Salazar Inst Biomed Sci, Oporto, Portugal

[4] Portuguese League Canc N, Res Dept, Oporto, Portugal

[5] Fernando Pessoa Univ, CEBIMED, Fac Hlth Sci, Oporto, Portugal

来源：

PLOS ONE | 2012年 / 7卷 / 06期

关键词：

CELL LUNG-CANCER; MESSENGER-RNA EXPRESSION; PLASMA DNA; NUCLEIC-ACIDS; TUMOR DNA; QUANTITATIVE-ANALYSIS; PROGNOSTIC VALUE; FOLLOW-UP; QUANTIFICATION; SERUM;

D O I：

10.1371/journal.pone.0038559

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];

摘要：

Purpose: The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease. Methods: We conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology. Results: We found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations. Conclusions: Quantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.

引用

页数：8

共 42 条

[1]

Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients [J].

Anker, P ;

Mulcahy, H ;

Chen, XQ ;

Stroun, M .

CANCER AND METASTASIS REVIEWS, 1999, 18 (01) :65-73

[2]

Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients [J].

Beau-Faller, M ;

Gaub, MP ;

Schneider, A ;

Ducrocq, X ;

Massard, G ;

Gasser, B ;

Chenard, MP ;

Kessler, R ;

Anker, P ;

Stroun, M ;

Weitzenblum, E ;

Pauli, G ;

Wihlm, JM ;

Quoix, E ;

Oudet, P .

INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (03) :361-370

[3]

Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? [J].

Bremnes, RM ;

Sirera, R ;

Camps, C .

LUNG CANCER, 2005, 49 (01) :1-12

[4]

Prognostic factors in non-small cell lung cancer - A decade of progress [J].

Brundage, MD ;

Davies, D ;

Mackillop, WJ .

CHEST, 2002, 122 (03) :1037-1057

[5]

Early detection of lung cancer using serum RNA or DNA markers: Ready for "prime time" or for validation? [J].

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3891-3893

[6]

Oncogenic virus-associated neoplasia: A role for cyclin D1 genotypes influencing the age of onset of disease? [J].

Catarino, R. ;

Pereira, D. ;

Breda, E. ;

Coelho, A. ;

Matos, A. ;

Lopes, C. ;

Medeiros, R. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 370 (01) :118-122

[7]

Catarino R, 2007, EJC SUPPL, V5, P184

[8]

Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer - A systematic review [J].

de Geus-Oei, Lioe-Fee ;

van der Heijden, Henricus F. M. ;

Corstens, Frans H. M. ;

Oyen, Wirn J. G. .

CANCER, 2007, 110 (08) :1654-1664

[9]

Detection and quantification of mutations in the plasma of patients with colorectal tumors [J].

Diehl, F ;

Li, M ;

Dressman, D ;

He, YP ;

Shen, D ;

Szabo, S ;

Diaz, LA ;

Goodman, SN ;

David, KA ;

Juhl, H ;

Kinzler, KW ;

Vogelstein, B .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) :16368-16373

[10]

Esteller M, 1999, CANCER RES, V59, P67

← 1 2 3 4 5 →